The Evaluation of the Safety and Effectiveness of Mesenchymal Stem Cell-derived Pleiotropic Factor in the Treatment of Donor Sites
Sponsor study identifier
interventional
20
1 country
1
Study Start
October 17, 2019
Actual (reported)Primary Completion
December 30, 2020
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
June 30, 2021
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Skin grafting is a standard treatment for deep wounds, but care of the donor site after transplantation is very important. The means of accelerating wound healing can increase overall patient satisfaction. In recent years, cytokine therapy has been an important strategy to promote tissue repair.Mesenchymal stem cells (MSC) have been considered the star cells that promote tissue repair. It works mainly through paracrine. Many biological effectors, including IGF-1, vascular endothelial growth factor (VEGF), TGF-β1, and hepatocyte growth factor (HGF), have been found and reported in various MSC conditioned media (MSC-CM), And play a role in promoting tissue repair and regeneration. In here, we aim to explore the MSC-CM-derived pleiotropic factor in treating donor sites and further evaluate its safety and effectiveness
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
June 30, 2021
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
October 17, 2019
Actual (reported)January 16, 2020
Actual (reported)January 21, 2020
Actual (reported)December 30, 2020
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
June 30, 2021
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
wound healing rate
Original wound area minus unhealed wound area divided by original wound area
1 month
Vancouver score
6 months
no intervention
mesenchymal stem cell conditioned medium-derived pleiotropic factor
After the patient is enrolled, when the patient's condition is stable, he is ready to undergo skin transplantation. For the donor site, an electric dermatome was used to remove the skin. The two donor areas of the same patient were divided into a pleiotropic factor group and a blank group randomly. After placing a coarse mesh vaseline oil gauze, then cover a certain thickness of sterile gauze and pressure bandage.
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
People's Liberation Army Central Air Force Hospital
Datong, Shanxi, China
Xiaobing Fu, doctor
Chinese PLA General Hospital
First Submitted
January 16, 2020
First Posted
January 21, 2020
Study Start
October 17, 2019
Actual (reported)Primary Completion
December 30, 2020
Estimated (date passed)Contact the study team to confirm eligibility.
This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
June 30, 2021
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Last Updated
May 12, 2020
Record last verified: 2020-05
Need to contact the researcher and open sharing after the researcher's consent
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: